Exact Sciences Q2 2024 GAAP EPS $(0.09) Beats $(0.32) Estimate, Sales $699.264M Beat $690.003M Estimate
Portfolio Pulse from Benzinga Newsdesk
Exact Sciences (NASDAQ:EXAS) reported Q2 2024 GAAP EPS of $(0.09), significantly beating the analyst estimate of $(0.32). The company also reported sales of $699.264 million, surpassing the $690.003 million estimate. This represents an 80% improvement in EPS and a 12.41% increase in sales compared to the same period last year.
July 31, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exact Sciences reported better-than-expected Q2 2024 results with EPS of $(0.09) beating the $(0.32) estimate and sales of $699.264 million surpassing the $690.003 million estimate. This indicates strong financial performance and growth.
The significant beat on both EPS and sales estimates, along with substantial year-over-year improvements, suggests strong financial health and growth potential for Exact Sciences. This is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100